Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8551292 | 0.78 | RAB9A (0.48) | HTR2ARAB9ASMN1; SMN2LMNA | |
| SCHEMBL3683946 | 0.73 | LMNA (0.39) | HTR2ASLC6A2SLC6A4CYP2D6RAB9A | |
| SCHEMBL22731139 | 0.73 | HTR2A (0.37) | HTR2ASLC6A2SLC6A4CYP2D6RAB9A | |
| SCHEMBL5083201 | 0.73 | SLC6A2 (0.37) | HTR2ASLC6A2SLC6A4CYP2D6RAB9A | |
| SCHEMBL18536393 | 0.73 | HTR2A (0.37) | HTR2ASLC6A2SLC6A4CYP2D6RAB9A | |
| SCHEMBL24999225 | 0.73 | MAOA (0.41) | HTR2ASLC6A2SLC6A4CYP2D6RAB9A | |
| SCHEMBL3420534 | 0.73 | MAOA (0.41) | HTR2ASLC6A2SLC6A4CYP2D6RAB9A | |
| SCHEMBL11419089 | 0.73 | SLC6A2 (0.37) | HTR2ASLC6A2SLC6A4CYP2D6RAB9A | |
| SCHEMBL3216781 | 0.73 | SLC6A2 (0.40) | HTR2ASLC6A2SLC6A4CYP2D6SMN1; SMN2 | |
| SCHEMBL5086903 | 0.73 | HTR2A (0.46) | HTR2ASLC6A2SLC6A4CYP2D6RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115397822-A | CBP/EP300 inhibitors and uses thereof | 南京药石科技股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-109496213-A | Spiro-compound and its preparation and application | 阿比德治疗公司 | 2019-03-19 | — | — | CN | disclosed |
| CN-108601769-A | Pyrazole compound and its preparation and application | 阿比德治疗公司 | 2018-09-28 | — | — | CN | disclosed |
| CN-108368053-A | Substituted benzazepine derivatives as antibacterial compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2018-08-03 | — | — | CN | disclosed |
| CN-106660982-A | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-105461589-A | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI AVENTIS | 2016-04-06 | — | — | CN | disclosed |
| CN-105418450-A | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS | 2016-03-23 | — | — | CN | disclosed |
| CN-102083432-B | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2016-02-17 | — | — | CN | disclosed |
| CN-102712589-B | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG | 2015-05-13 | — | — | CN | disclosed |
| CN-103382216-A | Cyanoisoquinoline compounds and methods of use thereof | FIBROGEN INC | 2013-11-06 | — | — | CN | disclosed |
| WO-2004094399-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CITALOPRAM HYDROBROMIDE | NATCO PHARMA LTD (IN) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004065375-A1 | PROCESSES FOR THE PREPARATION OF ESCITALOPRAM AND ITS PRECURSOR | NATCO PHARMA LIMITED (IN) | 2004-08-05 | — | — | WO | disclosed |
| US-20040133017-A1 | Process for the preparation of citalopram | NATCO PHARMA LIMITED (IN) | 2004-07-08 | — | — | US | disclosed |
| US-20040092755-A1 | Preparation of phthalanes | CIPLA LIMITED (IN) | 2004-05-13 | — | — | US | disclosed |
| EP-1368330-A1 | PROCESS FOR THE PREPARATION OF CITALOPRAM | Natco Pharma Limited (IN) | 2003-12-10 | — | — | EP | disclosed |
| EP-1366034-A1 | PREPARATION OF PHTHALANES | Cipla Ltd. (IN) | 2003-12-03 | — | — | EP | disclosed |
| WO-2003087081-A1 | PROCESS AND INTERMEDIATES FOR PREPARING ESCITALOPRAM | TORCAN CHEMICAL LTD. (CA) | 2003-10-23 | — | — | WO | disclosed |
| WO-2002070501-A1 | PREPARATION OF PHTHALANES | CIPLA LTD. (IN) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002066453-A1 | PROCESS FOR THE PREPARATION OF CITALOPRAM | NATCO PHARMA LIMITED (IN) | 2002-08-29 | — | — | WO | disclosed |
| WO-2001002383-A2 | PROCESS FOR THE SYNTHESIS OF CITALOPRAM | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133017-A1 | Process for the preparation of citalopram | F7, F13B, TFPI | HTR2A 176/4885SLC6A2 141/4885SLC6A4 41/4885 |
| US-20040092755-A1 | Preparation of phthalanes | CBR1, RCOR1, PBRM1 | HTR2A 482/4885SLC6A2 166/4885SLC6A4 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.